Schisandrin A restrains osteoclastogenesis by inhibiting reactive oxygen species and activating Nrf2 signalling.

Shuo NiZhi QianYin YuanDejian LiZeyuan ZhongFarnaz GhorbaniXu ZhangFangxue ZhangZhenhua ZhangZichen LiuBaoqing Yu

Published in: Cell proliferation (2020)

Our results showed the potential of anti-oxidant compound schisandrin A in the treatment of osteoporosis, highlighting Nrf2 as a novel promising target in osteoclast-related disease.

Keyphrases

reactive oxygen species
oxidative stress
signaling pathway
bone loss
postmenopausal women
bone mineral density
lps induced
inflammatory response
climate change